Immunocore (IMCR)

• Market cap: $1.4B
• 1 day: 1.94%
• 5 days: 9.27%
• 1 month: -5.43%
• 3 months: -2.10%
• 6 months: -15.82%
• Year to date: -4.73%
• 1 year: -47.95%
• 5 years: -34.24%
• 10 years: -34.24%
• Sector: Healthcare
• Industry: Biotechnology

About: Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.

Employees: 493

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

100% more funds holding in top 10

Funds holding in top 10: 1 [Q3] → 2 (+1) [Q4]

44% more call options, than puts

Call options by funds: $1.76M | Put options by funds: $1.22M

0.23% more ownership

Funds ownership: 90.51% [Q3] → 90.74% (+0.23%) [Q4]

5% less capital invested

Capital invested by funds: $1.41B [Q3] → $1.34B (-$70.8M) [Q4]

12% less funds holding

Funds holding: 128 [Q3] → 113 (-15) [Q4]

16% less repeat investments, than reductions

Existing positions increased: 36 | Existing positions reduced: 43

52% less first-time investments, than exits

New positions opened: 13 | Existing positions closed: 27

Research analyst outlook

5 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $33 16% upside
• Avg. target: $58 103% upside
• High target: $100 252% upside

5 analyst ratings

• positive: 3 60%
• neutral: 2 40%
• negative: 0 0%

JP Morgan Jessica Fye 53% 1-year accuracy 19 / 36 met price target	76% upside $50	Overweight Maintained	14 Apr 2025
Needham Gil Blum 12% 1-year accuracy 19 / 157 met price target	150% upside $71	Buy Reiterated	10 Apr 2025
Mizuho Graig Suvannavejh 26% 1-year accuracy 6 / 23 met price target	16% upside $33	Neutral Maintained	7 Apr 2025
HC Wainwright & Co. Patrick Trucchio 15% 1-year accuracy 28 / 186 met price target	252% upside $100	Buy Reiterated	12 Mar 2025
Morgan Stanley Andrew Galler 0% 1-year accuracy 0 / 1 met price target	23% upside $35	Equal-Weight Assumed	7 Mar 2025